Shopping Cart
Remove All
Your shopping cart is currently empty
Recaticimab (SHR-1209) is a humanized monoclonal antibody targeting PCSK9. By binding to PCSK9, Recaticimab promotes LDL receptor stabilization and surface expression on hepatocytes, leading to reduced plasma LDL cholesterol levels. Recaticimab is under study as a therapeutic candidate for hypercholesterolemia and related cardiovascular disorders.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $232 | - | In Stock | |
| 5 mg | $697 | - | In Stock | |
| 10 mg | $1,080 | - | In Stock | |
| 25 mg | $1,580 | - | In Stock | |
| 50 mg | $2,150 | - | In Stock |
| Description | Recaticimab (SHR-1209) is a humanized monoclonal antibody targeting PCSK9. By binding to PCSK9, Recaticimab promotes LDL receptor stabilization and surface expression on hepatocytes, leading to reduced plasma LDL cholesterol levels. Recaticimab is under study as a therapeutic candidate for hypercholesterolemia and related cardiovascular disorders. |
| Synonyms | SHR-1209, SHR1209 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Host Species | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Cas No. | 2361290-85-7 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.